Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 18463167
Chen Y, et al. (2008) EGF Transregulates Opioid Receptors through EGFR-mediated GRK2 Phosphorylation and Activation. Mol Biol Cell 19, 2973-83 18463167
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T358-p - DOR-1 (human)
Modsite: ATARERVtACtPsDG SwissProt Entrez-Gene
Orthologous residues
DOR‑1 (human): T358‑p, DOR‑1 (mouse): T358‑p, DOR‑1 (rat): T358‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), SKBr3 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DPDPE increase
EGF increase
AG1478 EGF inhibit treatment-induced increase

T361-p - DOR-1 (human)
Modsite: RERVtACtPsDGPGG SwissProt Entrez-Gene
Orthologous residues
DOR‑1 (human): T361‑p, DOR‑1 (mouse): T361‑p, DOR‑1 (rat): T361‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), SKBr3 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DPDPE increase
EGF increase
AG1478 EGF inhibit treatment-induced increase

S363-p - DOR-1 (human)
Modsite: RVtACtPsDGPGGGA SwissProt Entrez-Gene
Orthologous residues
DOR‑1 (human): S363‑p, DOR‑1 (mouse): S363‑p, DOR‑1 (rat): S363‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), SKBr3 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DPDPE increase
EGF increase
AG1478 EGF inhibit treatment-induced increase

S365-p - MOR-1 (human)
Modsite: SNIEQQNsTRIRQNt SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): S365‑p, MOR‑1 iso5 (human): S365‑p, MOR‑1 (mouse): S363‑p, MOR‑1 (rat): S363‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), SKBr3 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
Downstream Regulation
Effect of modification (function):  receptor internalization, altered

T372-p - MOR-1 (human)
Modsite: sTRIRQNtRDHPstA SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): T372‑p, MOR‑1 iso5 (human): T372‑p, MOR‑1 (mouse): T370‑p, MOR‑1 (rat): T370‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), SKBr3 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
Downstream Regulation
Effect of modification (function):  receptor internalization, altered

S377-p - MOR-1 (human)
Modsite: QNtRDHPstANTVDR SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): S377‑p, MOR‑1 iso5 (human): S377‑p, MOR‑1 (mouse): S375‑p, MOR‑1 (rat): S375‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), SKBr3 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
Downstream Regulation
Effect of modification (function):  receptor internalization, altered

Y13-p - GRK2 (cow)
Modsite: AVLADVSyLMAMEKS SwissProt Entrez-Gene
Orthologous residues
GRK2 (human): Y13‑p, GRK2 (mouse): Y13‑p, GRK2 (rat): Y13‑p, GRK2 (cow): Y13‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), SKBr3 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE EGFR (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE EGFR (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, microscopy-colocalization, phospho-motif antibody, pharmacological activator of upstream enzyme
KINASE Src (human) pharmacological inhibitor of upstream enzyme, transfection of constitutively active enzyme, phospho-motif antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
AG1478 EGF inhibit treatment-induced increase
PP2 EGF no effect upon treatment-induced increase
EGF Src (human) no effect upon treatment-induced increase dominant negative
Src (human) increase constitutively active
PP2 Src (human) inhibit treatment-induced increase
DPDPE increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced

Y86-p - GRK2 (cow)
Modsite: AKPLVEFyEEIKKyE SwissProt Entrez-Gene
Orthologous residues
GRK2 (human): Y86‑p, GRK2 (mouse): Y86‑p, GRK2 (rat): Y86‑p, GRK2 (cow): Y86‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), SKBr3 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE EGFR (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Src (human) pharmacological inhibitor of upstream enzyme, transfection of constitutively active enzyme, phospho-motif antibody
KINASE EGFR (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, microscopy-colocalization, phospho-motif antibody, pharmacological activator of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
AG1478 EGF inhibit treatment-induced increase
PP2 EGF no effect upon treatment-induced increase
EGF Src (human) no effect upon treatment-induced increase dominant negative
Src (human) increase constitutively active
PP2 Src (human) inhibit treatment-induced increase
DPDPE increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced

Y92-p - GRK2 (cow)
Modsite: FyEEIKKyEKLETEE SwissProt Entrez-Gene
Orthologous residues
GRK2 (human): Y92‑p, GRK2 (mouse): Y92‑p, GRK2 (rat): Y92‑p, GRK2 (cow): Y92‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), SKBr3 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE EGFR (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE EGFR (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, microscopy-colocalization, phospho-motif antibody, pharmacological activator of upstream enzyme
KINASE Src (human) pharmacological inhibitor of upstream enzyme, transfection of constitutively active enzyme, phospho-motif antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
AG1478 EGF inhibit treatment-induced increase
PP2 EGF no effect upon treatment-induced increase
EGF Src (human) no effect upon treatment-induced increase dominant negative
Src (human) increase constitutively active
PP2 Src (human) inhibit treatment-induced increase
DPDPE increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced